TP53 and breast cancer: Therefore, considering the results of this study, we could think to evaluate: i) the expression of TP53 and EGFR, and their mutations (T384S of EGFR and P151H of TP53) in sera of susceptible individuals to the environmental chemicals exposure to verify if they can be used as markers for BC and ii) the expression of ERCC4, KRAS and of hsa-mir-646 in individuals exposed to contamination of drinking water with arsenicals to understand if and what among these three molecules can be used as markers for BC initiation.